Sitravatinib

Description: Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRalpha/beta, PDGFR, and Axl. Target: VEGFR, Trk receptor, TAM Receptor, c-Kit, Ephrin Receptor, FLT, Discoidin Domain Receptor (DDR). Smiles: COCCNCc1ccc(nc1)-c1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)c2s1. References: Patwardhan PP et al. Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preClinicalal models of sarcoma. Oncotarget, 2016 Jan 26,7(4):4093-109.